GeneTex
United States (US)

Brk (Active) recombinant protein

Cat No. GTX65227

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human
APPLICATION

Application Note

133 nmol phosphate incorporated into Poly (Glu-Tyr) per minute per mg protein at 30ºC for 15 minutes using a final concentration of 50 uM ATP and total of 0.83 uCi/ul P-32.

Calculated MW

~80.0 kDa. ( Note )
PROPERTIES

Form

Liquid

Buffer

50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.25 mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, 25% glycerol

Storage

Store at -80ºC. Product is stable for at least 6-12 months.

Concentration

0.1mg/ml

Antigen Species

Human

Expression System

Baculovirus (Sf9 insect cells)

Purification


Purity was assessed by SDS-PAGE (≥95%) and by HPLC.

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

PTK6 protein tyrosine kinase6, PTK6 protein tyrosine kinase 6, BRK, PTK6

Background

BRK is another member of the non-receptor tyrosine kinases (PTKs) that contains an amino terminal SH3 and SH2 domains as well as the catalytic domain (1). Although BRK shows strongest sequence similarity to members of the Src family, there are several key structural and regulatory differences that place it on its own amongst non-receptor PTKs. The genomic structure of BRK consists of 8 exons, whose boundaries are distinct from other non-receptor PTK family members (2). Alternate splicing of the primary BRK transcript generates a distinct mRNA which encodes a truncated protein consisting of an SH3 domain and a novel C-terminal proline rich sequence. Brk transcript is expressed in the human breast tumor cell line and expression of a tumor derived Brk cDNA in 22 embryonic fibroblasts and human mammary epithelial cells supports anchorage independent growth, and in the latter potentiates the mitogenic response to epidermal growth factor. Brk expression is low or undetectable in normal mammary tissue and benign lesions. However, approximately two-thirds of breast tumors express appreciable levels and 27% of tumors over express BRK by fivefold or more (up to 43x). This expression pattern is mirrored in comparison of cell lines derived either from normal mammary epithelial cells or from carcinomas (3).

Research Area

Package List Price ($)
$ 349